Abraxis BioScience (ABII)

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and to acquire various intellectual property rights and to make other investments.

Net cash used for the acquisition of property, plant and equipment for the year ended December 31, 2009, 2008 and 2007 totaled $94.5, $43.7 million and $40.6 million, respectively. The expenditures in 2009 related primarily to the purchase of our Costa Mesa research facility and the modernization of our Melrose Park, Illinois and Phoenix, Arizona manufacturing facilities. Net cash paid for acquisition of $2.6 million related to net milestone payments for Shimoda Biotech (Pty) Ltd and Platco Technologies (Pty) Ltd. Additionally, we made investments in various entities for $10.7 million and purchased notes receivable of $4.7 million. In 2009, we also had proceeds from the sale of marketable securities of $3.7 million and proceeds of $2.0 million from the sale of our subsidiary in Barbengo, Switzerland.

In 2008, we purchased $19.7 million in marketable securities, which included $5.2 million for our investments in ProMetic Life Sciences, Inc., $5.4 million in other equity marketable securities and $9.1 million in debt marketable securities. Additionally, in 2008, we purchased $2.6 million in warrants and investment rights and $4.5 million in other investments. We acquired 100% of the equity of both Shimoda Biotech (Pty) Ltd and Platco Technologies (Pty) Ltd. for $15.1 million.

Net cash used for the acquisition of product license rights and other non-current assets totaled $4.1 million for the year ended December 31, 2007.

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and to acquire various intellectual property rights.

Net cash used for the acquisition of property, plant and equipment for the three months ended March 31, 2009 totaled $19.0 million. The majority of this amount related to expenditures for the modernization of our Melrose Park, Illinois and Phoenix, Arizona manufacturing facilities. For the three months ended March 31, 2009, we had proceeds from the sale of marketable securities of $3.7 million. Additionally, in 2009, we received net proceeds of $2.0 million from the sale of our subsidiary in Barbengo, Switzerland.

Net cash used for acquisition of property, plant and equipment for the three months ended March 31, 2008 was $1.9 million. Additionally, we purchased $4.5 million in marketable securities and other investments during the first quarter of 2008.

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and to acquire various intellectual property rights. Additionally, we purchased investments in marketable securities, which we classify as available-for-sale securities.

Net cash used for the acquisition of property, plant and equipment for the year ended December 31, 2008, 2007 and 2006 totaled $43.7 million, $40.6 million and $64.4 million, respectively. The expenditures in 2008 related primarily to the modernization of our Melrose Park, Illinois and Phoenix, Arizona manufacturing facilities. In 2007, we increased capital investments in our core manufacturing and development capabilities including our 90,000 square foot active pharmaceutical ingredients plant in Puerto Rico and our Phoenix, Arizona manufacturing facility. Expenditures in 2006 related primarily to the purchase of the corporate aircraft.

In 2008, we purchased $19.7 million in marketable securities, which included $5.2 million for our investments in ProMetic Life Sciences, Inc, $5.4 million in other equity marketable securities and $9.1 million in debt marketable securities. Additionally, in 2008, we purchased $2.6 million in warrants and investment rights and $4.5 million in other investments. We acquired 100% of the equity of both Shimoda Biotech (Pty) Ltd and Platco Technologies (Pty) Ltd. for $15.1 million.

Net cash used for the acquisition of product license rights and other non-current assets totaled $4.1 million and $14.8 million for the years ended December 31, 2007 and 2006. The decrease from 2006 was due to the purchase of an office building and land in Culver City, California in 2006.

Investing Activities

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and to acquire various intellectual property rights. Additionally, we purchased investments and marketable securities, which we classify as available-for-sale securities.

Net cash used for the acquisition of property, plant and equipment for the nine months ended September 30, 2008 totaled $22.6 million. The majority of this amount related to expenditures for the modernization of our Melrose Park, Illinois and Phoenix, Arizona manufacturing facilities. For the nine months ended September 30, 2008, we purchased $16.4 million in marketable securities and other investments. Additionally, in 2008, net cash paid for acquisition of $15.0 million relates to our acquisition of Shimoda Biotech and Platco Technologies.

Net cash used for acquisition of property, plant and equipment for the nine months ended September 30, 2007 was $35.5 million. This amount primarily related to the acquisition of our Puerto Rico facility. In addition, we paid $1.8 million for investments and marketable securities in 2007.

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and to acquire various intellectual property rights. Additionally, we purchased investments and marketable securities, which we classify as available for sale securities.

Net cash used for the acquisition of property, plant and equipment for the six months ended June 30, 2008 totaled $13.2 million. The majority of this amount related to expenditures for the modernization of our Melrose Park, Illinois and Phoenix, Arizona manufacturing facilities. For the six months ended June 30, 2008, we purchased $9.4 million in marketable securities and other investments. Additionally, in 2008, net cash paid for acquisition of $15.0 million relates to our acquisition of Shimoda Biotech and Platco Technologies.

Net cash used for acquisition of property, plant and equipment for the six months ended June 30, 2007 was $16.4 million. This amount primarily related to the acquisition of our Puerto Rico facility. In addition, we paid $1.8 million for investments and marketable securities in 2007.

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and to acquire various intellectual property rights. Additionally, we purchase investments and marketable securities, which we intend to own long-term and are classified as available for sale securities.

Net cash used for the acquisition of property, plant and equipment for the three-month periods ended March 31, 2008 and 2007, totaled $1.9 million and $11.3 million, respectively. This decrease was primarily due to the acquisition of our Puerto Rico manufacturing facility in 2007. For the three months ended March 31, 2008, we purchased $4.5 million in marketable securities and other investments compared to $0.5 million for the same period in 2007.

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and outlays necessary to acquire various intellectual property rights.

Net cash used for the acquisition of product license rights and other non-current assets totaled $4.3 million, $14.8 million and $1.2 million for the years ended December 31, 2007, 2006 and 2005, respectively. The decrease from 2006 was because of the purchase of an office building and land in Culver City, California in 2006.

Net cash used for the acquisition of property, plant and equipment for the year ended December 31, 2007, 2006 and 2005 totaled $40.6 million, $64.4 million and $17.2 million, respectively. The 2007 additions included increased capital investment in our core manufacturing and development capabilities in 2007, including our 90,000 square foot active pharmaceutical ingredients plant in Puerto Rico and our Phoenix, Arizona manufacturing facility. The 2006 additions primarily included the purchase of the corporate aircraft. Purchases of property, plant and equipment in 2005 were primarily related to improvements in our manufacturing and development capabilities.

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and outlays necessary to acquire various intellectual property rights.

Net cash used for the acquisition of product license rights and other non-current assets totaled $1.8 million and $2.1 million for the nine-month periods ending September 30, 2007 and 2006, respectively. Net cash used for the acquisition of property, plant and equipment for the nine-month periods ending September 30, 2007 and 2006 totaled $35.5 million and $74.0 million, respectively. The decrease from 2006 was due primarily to the purchase of a corporate aircraft in 2006, which was offset by increased capital investment in our core manufacturing and development capabilities in 2007.

Investing Activities

Our investing activities have included capital expenditures necessary to expand and maintain our manufacturing capabilities and infrastructure and outlays necessary to acquire various or intellectual property rights.

60

Table of Contents

Net cash used for the acquisition of product license rights and other non-current assets totaled $1.8 million, and $2.7 million for the six-month periods ending June 30, 2007 and 2006, respectively. Net cash used for the acquisition of property, plant and equipment for the six-month periods ending June 30, 2007 and 2006, totaled $16.4 million and $23.4 million, respectively.

Net cash used for the acquisition of product license rights and other non-current assets totaled $14.8 million, $1.2 million and $3.3 million for the years ended December 31, 2006, 2005 and 2004, respectively. The increase in 2006 resulted from the purchase of an office building and land in Culver City, California.

Net cash used for the acquisition of property, plant and equipment totaled $64.4 million, $17.2 million and $26.0 million for the years ended December 31, 2006, 2005 and 2004, respectively. The increase in 2006 was due primarily to the purchase of a corporate aircraft and increased capital investment in our core manufacturing and development capabilities. Purchases of property, plant and equipment in 2005 and 2004 were primarily related to improvements in our manufacturing and development capabilities.